IPR v. Ex Parte Reexam Strategy Considerations
February 7, 2024, 7:16 AM
Looking forward to presenting at the AIPLA IP Practice in Japan Mid-Winter Program in Houston, TX next week!
I will be discussing the strategic considerations for Inter Partes Review (IPR) versus Ex Parte Reexamination, including:
- The procedural differences between IPR and Ex Parte Reexamination and associated statistics
- The circumstances when one may be preferable over the other
- The effects of timing and estoppel in parallel litigations
My colleague, Jason Murata, another partner in Axinn’s Intellectual Property group, will be covering, “Recent Developments in the Generic Pharma Industry in the U.S.”

To subscribe to our publications, click here.
News & Insights
News & Insights
LCA 2026 Renaissance Symposium XX
Speaking Engagement
Antitrust
Concurrences New Frontiers of Antitrust Conference 2026
Sponsorship
Antitrust
Stakeholders 26th Annual CYOC Conference
Event
Antitrust
Hot Topics in Health Care Antitrust
Podcast
Antitrust
Jimmy Attridge Repeats Recognition on Washingtonian Magazine’s 2026 Top Lawyers List
Awards & Recognitions
Antitrust
AIC General Counsel Day 2026
Speaking Engagement
Antitrust
ALFDP 20th Anniversary Annual Conference
Event
Antitrust
Antitrust After the Midterms: Planning for a Blue Wave of Congressional Investigations
Axinn Viewpoints
Antitrust
GCR Live: Women in Antitrust 2026
Sponsorship
Antitrust
GICLI Annual Meeting 2026
Sponsorship
Antitrust